Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nelfinavir mesylate
Drug ID BADD_D01550
Description Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Indications and Usage Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
Marketing Status Prescription; Discontinued
ATC Code J05AE04
DrugBank ID DB00220
KEGG ID D00899
MeSH ID D019888
PubChem ID 64142
TTD Drug ID Not Available
NDC Product Code 63010-027; 63010-010
Synonyms Nelfinavir | Viracept | AG 1343 | AG1343 | AG-1343 | Nelfinavir Mesylate | Mesylate, Nelfinavir | Nelfinavir Monomethane Sulfonate | Monomethane Sulfonate, Nelfinavir | Sulfonate, Nelfinavir Monomethane
Chemical Information
Molecular Formula C33H49N3O7S2
CAS Registry Number 159989-65-8
SMILES CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O )O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Insulin resistanceLipoprotein lipaseP06858T28692Not Available
Insulin resistanceTranscription factor AP-2-alphaP05549T71317Not Available
Insulin resistanceAdiponectinQ15848T15572Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rhabdomyolysis15.05.05.002--
Rhinitis22.07.03.006; 11.01.13.004--
Seizure17.12.03.001--
Sexual dysfunction19.08.05.002; 21.03.02.003--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Suicidal ideation19.12.01.003--
Thrombocytopenia01.08.01.002--Not Available
Torsade de pointes02.03.04.005--Not Available
Urine abnormality20.02.01.013--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Fat redistribution14.08.04.002--Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.008--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Body fat disorder14.08.04.012--Not Available
Haemorrhage24.07.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hepatic enzyme increased13.03.01.019--Not Available
Connective tissue disorder15.06.01.006--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages